{"id":"https://openalex.org/W3211996152","doi":"https://doi.org/10.1136/jitc-2021-sitc2021.553","title":"553 First-in-class inhibitors of ERAP1 alter the immunopeptidome of cancer, driving a differentiated T cell response leading to tumor growth inhibition","display_name":"553 First-in-class inhibitors of ERAP1 alter the immunopeptidome of cancer, driving a differentiated T cell response leading to tumor growth inhibition","publication_year":2021,"publication_date":"2021-11-01","ids":{"openalex":"https://openalex.org/W3211996152","doi":"https://doi.org/10.1136/jitc-2021-sitc2021.553","mag":"3211996152"},"language":"en","primary_location":{"id":"doi:10.1136/jitc-2021-sitc2021.553","doi":"https://doi.org/10.1136/jitc-2021-sitc2021.553","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2021-sitc2021.553","pdf_url":"https://jitc.bmj.com/content/jitc/9/Suppl_2/A583.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and Young Investigator Award Abstracts","raw_type":"proceedings-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://jitc.bmj.com/content/jitc/9/Suppl_2/A583.full.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5032039751","display_name":"Peter Ian Joyce","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267319","display_name":"Grey Wolf Therapeutics Limited (United Kingdom)","ror":"https://ror.org/026dwz758","country_code":"GB","type":"company","lineage":["https://openalex.org/I4405267319"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Peter Joyce","raw_affiliation_strings":["Grey Wolf Therapeutics Ltd, Oxford, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Grey Wolf Therapeutics Ltd, Oxford, UK","institution_ids":["https://openalex.org/I4405267319"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062898783","display_name":"Martin Quibell","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Martin Quibell","raw_affiliation_strings":["Grey Wolf Therapeutics, Oxford, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Grey Wolf Therapeutics, Oxford, UK","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013159491","display_name":"Jason J. Shiers","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jason Shiers","raw_affiliation_strings":["Sygnature Discovery, Nottingham, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sygnature Discovery, Nottingham, UK","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Carmen Tong","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Carmen Tong","raw_affiliation_strings":["Sygnature Discovery, Nottingham, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sygnature Discovery, Nottingham, UK","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Kristopher Clark","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kristopher Clark","raw_affiliation_strings":["Sygnature Discovery, Nottingham, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sygnature Discovery, Nottingham, UK","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090536136","display_name":"Nicola Ternette","orcid":"https://orcid.org/0000-0002-9283-0743","observed_orcids":["https://orcid.org/0000-0002-9283-0743"]},"institutions":[{"id":"https://openalex.org/I40120149","display_name":"University of Oxford","ror":"https://ror.org/052gg0110","country_code":"GB","type":"education","lineage":["https://openalex.org/I40120149"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Nicola Ternette","raw_affiliation_strings":["University of Oxford, Oxford, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Oxford, Oxford, UK","institution_ids":["https://openalex.org/I40120149"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039313243","display_name":"Kate Anderton","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kate Anderton","raw_affiliation_strings":["Grey Wolf Therapeutics, Oxford, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Grey Wolf Therapeutics, Oxford, UK","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029747131","display_name":"Jessica Sette","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jessica Sette","raw_affiliation_strings":["Grey Wolf Therapeutics, Oxford, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Grey Wolf Therapeutics, Oxford, UK","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015292930","display_name":"Wayne Paes","orcid":"https://orcid.org/0000-0002-0529-2765","observed_orcids":["https://orcid.org/0000-0002-0529-2765"]},"institutions":[{"id":"https://openalex.org/I40120149","display_name":"University of Oxford","ror":"https://ror.org/052gg0110","country_code":"GB","type":"education","lineage":["https://openalex.org/I40120149"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Wayne Paes","raw_affiliation_strings":["University of Oxford, Oxford, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Oxford, Oxford, UK","institution_ids":["https://openalex.org/I40120149"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5068519558","display_name":"Andrew J. Leishman","orcid":"https://orcid.org/0000-0003-4273-8188","observed_orcids":["https://orcid.org/0000-0003-4273-8188"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Andrew Leishman","raw_affiliation_strings":["Grey Wolf Therapeutics, Oxford, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Grey Wolf Therapeutics, Oxford, UK","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2490,"currency":"USD","value_usd":2490},"apc_paid":{"value":2490,"currency":"USD","value_usd":2490},"fwci":null,"has_fulltext":true,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"A583","last_page":"A583"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.8384000062942505,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.8384000062942505,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.15060000121593475,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12576","display_name":"vaccines and immunoinformatics approaches","score":0.007000000216066837,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/immunopeptidome","display_name":"immunopeptidome","score":0.9559999704360962},{"id":"https://openalex.org/keywords/antigen-presentation","display_name":"antigen presentation","score":0.628000020980835},{"id":"https://openalex.org/keywords/tcr-repertoire","display_name":"T cell receptor repertoire","score":0.8560000061988831},{"id":"https://openalex.org/keywords/tumor-infiltrating-t-cells","display_name":"tumor-infiltrating T cells","score":0.7549999952316284},{"id":"https://openalex.org/keywords/anti-pd-1-combination-therapy","display_name":"anti-PD-1 combination therapy","score":0.9129999876022339},{"id":"https://openalex.org/keywords/tumor-growth-inhibition","display_name":"tumor growth inhibition","score":0.6880000233650208},{"id":"https://openalex.org/keywords/peptide-length","display_name":"peptide length","score":0.45399999618530273},{"id":"https://openalex.org/keywords/hla-diversity","display_name":"HLA diversity","score":0.5590000152587891},{"id":"https://openalex.org/keywords/cancer-immunotherapy-biomarkers","display_name":"cancer immunotherapy biomarkers","score":0.7400000095367432},{"id":"https://openalex.org/keywords/syngeneic-mouse-model","display_name":"syngeneic mouse model","score":0.8519999980926514},{"id":"https://openalex.org/keywords/ct26-cells","display_name":"CT26 cells","score":0.6759999990463257},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.43799999356269836},{"id":"https://openalex.org/keywords/combination-therapy-with-chemotherapy-and-radiotherapy","display_name":"combination therapy with chemotherapy and radiotherapy","score":0.5979999899864197}],"concepts":[{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5427607893943787},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.5127878785133362},{"id":"https://openalex.org/C167672396","wikidata":"https://www.wikidata.org/wiki/Q417800","display_name":"CD8","level":3,"score":0.5020010471343994},{"id":"https://openalex.org/C19317047","wikidata":"https://www.wikidata.org/wiki/Q412037","display_name":"T-cell receptor","level":4,"score":0.49060073494911194},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.4812862277030945},{"id":"https://openalex.org/C154317977","wikidata":"https://www.wikidata.org/wiki/Q376266","display_name":"Cytotoxic T cell","level":3,"score":0.4392826557159424},{"id":"https://openalex.org/C188280979","wikidata":"https://www.wikidata.org/wiki/Q911125","display_name":"Human leukocyte antigen","level":3,"score":0.43051135540008545},{"id":"https://openalex.org/C2780674031","wikidata":"https://www.wikidata.org/wiki/Q2012719","display_name":"Cancer immunotherapy","level":4,"score":0.42970022559165955},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.3911837935447693},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.3693130910396576},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.36137357354164124},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.31212568283081055},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.29836639761924744},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.15875768661499023},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.07789942622184753}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1136/jitc-2021-sitc2021.553","doi":"https://doi.org/10.1136/jitc-2021-sitc2021.553","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2021-sitc2021.553","pdf_url":"https://jitc.bmj.com/content/jitc/9/Suppl_2/A583.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and Young Investigator Award Abstracts","raw_type":"proceedings-article"},{"id":"pmh:oai:doaj.org/article:f77fbe78c6a14420843d4d1a5af88195","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/f77fbe78c6a14420843d4d1a5af88195","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1136/jitc-2021-sitc2021.553","doi":"https://doi.org/10.1136/jitc-2021-sitc2021.553","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2021-sitc2021.553","pdf_url":"https://jitc.bmj.com/content/jitc/9/Suppl_2/A583.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and Young Investigator Award Abstracts","raw_type":"proceedings-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3211996152.pdf","grobid_xml":"https://content.openalex.org/works/W3211996152.grobid-xml"},"referenced_works_count":8,"referenced_works":["https://openalex.org/W2049553585","https://openalex.org/W2081921422","https://openalex.org/W2153228313","https://openalex.org/W2736476343","https://openalex.org/W2774712455","https://openalex.org/W2799817264","https://openalex.org/W2945679805","https://openalex.org/W2988620928"],"related_works":["https://openalex.org/W3100797614","https://openalex.org/W3178271449","https://openalex.org/W2163253520","https://openalex.org/W3083182260","https://openalex.org/W4308385294","https://openalex.org/W4362594837","https://openalex.org/W4282938850","https://openalex.org/W4306150170","https://openalex.org/W7019148924","https://openalex.org/W2952137149"],"abstract_inverted_index":{"Background":[0],"Clinical":[1],"data":[2,363],"demonstrates":[3],"increased":[4,25,213],"antigen":[5,190,277],"presentation":[6],"diversity":[7,31],"is":[8,53,246],"an":[9,54],"important":[10],"factor":[11],"in":[12,77,98,205,232,239,293,316,357,381,411,484],"determining":[13],"response":[14,43,437],"rates":[15],"to":[16,21,44,106,130,144,212,288,311,345,390,408,438],"checkpoint":[17,45,140,439],"inhibitors.1":[18],"In":[19,542],"addition":[20],"tumor":[22,87,100,148,168,233,253,290,327,354,360],"mutational":[23],"burden,":[24],"HLA":[26,29,196,431,456],"heterozygosity":[27],"and":[28,40,62,86,102,117,138,167,195,198,209,221,229,258,278,323,339,353],"evolutionary":[30],"are":[32,261,303],"non-overlapping":[33],"factors":[34],"which":[35,368],"further":[36],"diversify":[37],"the":[38,74,93,113,155,175,188,224,240,273,276,306,337,365,372,382,485],"immunopeptidome":[39,338],"improve":[41],"clinical":[42],"therapies.2":[46],"3":[47],"Endoplasmic":[48],"reticulum":[49],"aminopeptidase":[50,508],"1":[51],"(ERAP1)":[52],"enzyme":[55],"that":[56,184,267],"trims":[57],"peptides":[58,566],"loaded":[59],"into":[60,112,217,272],"classical":[61],"nonclassical":[63],"MHC":[64,480],"Class":[65],"I":[66,433,458,482],"molecules.4":[67],"5":[68],"Ablation":[69],"of":[70,81,95,104,109,174,177,223,249,264,308,374,455,462,522,528,564],"mouse":[71,118,147,296,359],"ERAAP":[72,529],"modifies":[73],"immunopeptidome,":[75,241],"resulting":[76],"improved":[78],"immunogenicity,":[79],"generation":[80,505],"CD8+":[82],"T":[83,156,206,214,279,350,422],"cell":[84,120,157,165,180,207,215,280,351,413],"responses":[85,315],"growth":[88,169,291,355],"inhibition.6":[89],"7":[90],"We":[91,302],"report":[92],"characterisation":[94],"ERAP1":[96,124,135,185,194,201,244,285,309,333,377],"inhibitors":[97,125,310,334],"syngeneic":[99,146,219,295,358],"models":[101,297],"development":[103,379],"biomarkers":[105,266,389],"enable":[107],"translation":[108],"this":[110],"mechanism":[111,250],"clinic.":[114,274],"Methods":[115],"Human":[116],"cancer":[119,179,436,463,550],"lines":[121,181],"treated":[122],"with":[123,137,300,318,341],"were":[126,142],"assessed":[127],"by":[128,151,243,506],"immunopeptidomics8":[129],"profile":[131],"peptide":[132,236,477,504],"repertoire":[133,191,226,256,348],"changes.":[134],"inhibitor":[136,378],"without":[139],"inhibition":[141,186,202,286,292,356],"used":[143],"treat":[145],"models,":[149],"followed":[150],"analysing":[152],"effects":[153],"on":[154],"receptor":[158],"(TCR)":[159],"repertoire,":[160],"RNA":[161,259],"sequencing":[162,260],"profile,":[163],"immune":[164,314],"infiltration":[166,216,352],"inhibition.":[170],"Results":[171],"Extensive":[172],"analysis":[173,257],"immunopeptidomes":[176],"diverse":[178,193],"robustly":[182],"show":[183],"modulates":[187],"cancer-related":[189],"across":[192,325],"genotypes":[197],"cancer-type":[199],"backgrounds.":[200],"drives":[203],"changes":[204,238,281],"activation":[208],"response,":[210],"leading":[211],"CT26":[218],"tumors":[220],"alteration":[222],"TCR":[225,255,347],"at":[227],"early":[228],"late":[230],"timepoints":[231],"growth.":[234],"Consistent":[235],"length":[237],"caused":[242],"inhibition,":[245],"a":[247,549],"proof":[248,263],"biomarker,":[251],"whilst":[252],"immunohistochemisty,":[254],"potential":[262,307,373],"principle":[265],"can":[268],"all":[269],"be":[270],"translated":[271],"Importantly,":[275],"we":[282,369],"see":[283],"following":[284],"lead":[287],"robust":[289],"different":[294,326],"when":[298],"combined":[299],"anti-PD-1.":[301],"also":[304],"exploring":[305],"enhance":[312],"tumour":[313],"combination":[317,340],"additional":[319],"therapies":[320],"(e.g.":[321],"chemotherapy":[322],"radiotherapy),":[324],"microenvironments.":[328],"Conclusions":[329],"Grey":[330],"Wolf":[331],"Therapeutics":[332],"significantly":[335],"modify":[336],"anti":[342],"PD-1":[343,409],"leads":[344],"significant":[346],"change,":[349],"models.":[361],"These":[362],"provide":[364],"foundation":[366],"from":[367],"will":[370],"explore":[371],"our":[375],"first-in-class":[376],"candidate":[380],"clinic,":[383],"as":[384,386,548],"well":[385],"identifying":[387],"useful":[388],"demonstrate":[391],"desired":[392],"biological":[393],"activity.":[394],"References":[395],"Rizvi":[396],"N,":[397,469,471],"Hellmann":[398],"MD,":[399],"Snyder":[400],"A,":[401,493],"et":[402,428,451,474,498,519,540],"al.":[403,475,499,520],"Mutational":[404],"landscape":[405],"determines":[406],"sensitivity":[407],"blockade":[410,440],"non\u2013small":[412],"lung":[414],"cancer.":[415],"Science":[416,442],"2015;348(6230):124\u2013128.":[417],"Chowell":[418,445],"D,":[419,446],"uc":[420],"G":[421],"Morris":[423],"LGT,2":[424],"3,":[425],"Grigg":[426],"CM,":[427],"al":[429,452,541],"Patient":[430],"class":[432,457,481],"genotype":[434,459],"influences":[435],"immunotherapy.":[441,464],"2018;359":[443],"(6375):582\u2013587.":[444],"Chirag":[447],"Krishna,":[448],"Federica":[449],"Pierini,":[450],"Evolutionary":[453],"divergence":[454],"impacts":[460],"efficacy":[461],"Nature":[465,553],"Medicine":[466],"2019;25(11):1715\u20131720.":[467],"Shastri":[468],"Nagarajan":[470],"Lind":[472],"KC,":[473],"Monitoring":[476],"processing":[478],"for":[479,502,567],"molecules":[483],"endoplasmic":[486],"reticulum.":[487],"Curr":[488],"Opin":[489],"Immunol":[490,511,532],"2014;26:123\u2013127.":[491],"Mpakali":[492],"Maben":[494],"Z,":[495],"Stern":[496],"LJ,":[497],"Molecular":[500],"pathways":[501],"antigenic":[503],"ER":[507],"1.":[509],"Mol":[510],"2018;13:50\u201357.":[512],"James":[513],"E,":[514],"Bailey":[515],"I,":[516],"Sugiyarto":[517],"G,":[518],"Induction":[521],"protective":[523],"antitumor":[524],"immunity":[525],"through":[526],"attenuation":[527],"function.":[530],"J":[531],"2013;190(11):5839\u20135846.":[533],"Manguso":[534],"RT,":[535],"Pope,":[536],"HW,":[537],"MD":[538],"Zimmer,":[539],"vivo":[543],"CRISPR":[544],"screening":[545],"identifies":[546],"Ptpn2":[547],"immunotherapy":[551],"target.":[552],"2017;547(7664):413\u2013418.":[554],"Purcell":[555],"AW,":[556],"Ramarathinam":[557],"SH,":[558],"Ternette":[559],"N.":[560],"Mass":[561],"spectrometry\u2013based":[562],"identification":[563],"MHC-bound":[565],"immunopeptidomics.":[568],"Nat":[569],"Protoc":[570],"2019;14(6):1687\u20131707.":[571]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1}],"updated_date":"2026-11-02T09:45:03.842371","created_date":"2021-11-22T00:00:00"}